Study identification

PURI

https://redirect.ema.europa.eu/resource/39810

EU PAS number

EUPAS34303

Study ID

39810

Official title and acronym

A Multicenter, Multi-countiy Retrospective Cohort Study to Evaluate the Clinical Outcomes in Adults with Severe COVID-19

DARWIN EU® study

No

Study countries

Belgium
France
Hong Kong
Italy
Korea, Democratic People's Republic of
Singapore
Spain
United Kingdom
United States

Study description

GS-US-540-5807: The primary objectives of this study were to assess the clinical course and outcome of adults with severe COVID-19 assessed by: 1) a 7-point ordinal scale on Day 14, and 2) all-cause mortality at Day 28.

Study status

Finalised
Research institutions and networks

Institutions

Gilead Sciences
First published:
12/02/2024
InstitutionPharmaceutical company
Multiple centres: 50 centres are involved in the study

Contact details

Gilead Study Director

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Actual:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Gilead Sciences
Study protocol
Initial protocol
English (186.73 KB - PDF)View document
Updated protocol
English (193.8 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

Not applicable